DE60327407D1 - Immunmodulierende peptide - Google Patents

Immunmodulierende peptide

Info

Publication number
DE60327407D1
DE60327407D1 DE60327407T DE60327407T DE60327407D1 DE 60327407 D1 DE60327407 D1 DE 60327407D1 DE 60327407 T DE60327407 T DE 60327407T DE 60327407 T DE60327407 T DE 60327407T DE 60327407 D1 DE60327407 D1 DE 60327407D1
Authority
DE
Germany
Prior art keywords
immunomodulating peptides
immunomodulating
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60327407T
Other languages
English (en)
Inventor
Sung-Ho Ryu
Pann-Ghill Suh
Yoe-Sik Bae
Ji-Young Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pohang University of Science and Technology Foundation POSTECH
Posco Holdings Inc
Original Assignee
Posco Co Ltd
Pohang University of Science and Technology Foundation POSTECH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Posco Co Ltd, Pohang University of Science and Technology Foundation POSTECH filed Critical Posco Co Ltd
Application granted granted Critical
Publication of DE60327407D1 publication Critical patent/DE60327407D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
DE60327407T 2002-01-29 2003-01-28 Immunmodulierende peptide Expired - Lifetime DE60327407D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35293002P 2002-01-29 2002-01-29
PCT/KR2003/000191 WO2003064447A2 (en) 2002-01-29 2003-01-28 Immune-modulating peptide

Publications (1)

Publication Number Publication Date
DE60327407D1 true DE60327407D1 (de) 2009-06-10

Family

ID=27663154

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60327407T Expired - Lifetime DE60327407D1 (de) 2002-01-29 2003-01-28 Immunmodulierende peptide

Country Status (8)

Country Link
US (1) US7030090B2 (de)
EP (2) EP1414849B1 (de)
JP (2) JP4474163B2 (de)
KR (4) KR100839098B1 (de)
CN (2) CN100569796C (de)
CA (1) CA2446872C (de)
DE (1) DE60327407D1 (de)
WO (1) WO2003064447A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517857B2 (en) * 2002-01-29 2009-04-14 Posco Immune-modulating peptide
WO2004067020A1 (en) * 2003-01-30 2004-08-12 Pohang University Of Science And Technology Dna vaccine composition with enhanced immunogenicity
US20050234004A1 (en) * 2004-01-26 2005-10-20 Brett Premack Compositions and methods of use of W-peptides
ES2533697T3 (es) 2004-08-23 2015-04-14 Yeda Research And Development Co., Ltd. Inhibidores peptídicos para mediar respuestas de estrés
ITMI20061607A1 (it) * 2006-08-09 2008-02-10 Maria Vincenza Carriero Peptidi con attivita farmacologica
US8877203B2 (en) 2007-11-02 2014-11-04 Postech Academy-Industry Foundation Composition and method for preventing and treating immune-related disorder
KR20100123240A (ko) * 2009-05-15 2010-11-24 포항공과대학교 산학협력단 호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법
US20140088017A1 (en) 2011-05-23 2014-03-27 Yeda Research And Development Co., Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
KR101708945B1 (ko) * 2011-11-15 2017-02-22 성균관대학교산학협력단 인간 호중구 세포의 활성을 조절하는 신규한 펩타이드
US9527888B2 (en) * 2012-05-11 2016-12-27 Gemvax & Kael Co., Ltd. Anti-inflammatory peptides and composition comprising the same
WO2014204229A2 (ko) * 2013-06-21 2014-12-24 성균관대학교산학협력단 펩타이드를 유효성분으로 포함하는 류마티스 관절염 예방 또는 치료용 약학적 조성물
KR101668590B1 (ko) * 2014-06-19 2016-10-25 전남대학교병원 재협착 억제 및 재내피화 촉진을 위한 신규한 펩타이드 화합물 및 이의 제조방법
KR101959237B1 (ko) 2018-02-26 2019-03-20 주식회사 굳티셀 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
KR102227522B1 (ko) * 2018-07-16 2021-03-12 부산대학교 산학협력단 GHKWKYMVm 펩타이드를 포함하는 염증성 피부질환의 예방 또는 치료용 약학적 조성물
CN109679981A (zh) * 2019-02-21 2019-04-26 武汉大学 一种甲酰基肽定向进化噬菌体及其制备方法与应用
KR102094747B1 (ko) 2019-03-08 2020-03-30 주식회사 굳티셀 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
KR102067402B1 (ko) 2019-03-08 2020-01-17 주식회사 굳티셀 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
KR102382610B1 (ko) * 2019-12-24 2022-04-05 차의과학대학교 산학협력단 기능 강화된 중간엽 줄기세포를 포함하는 간질환의 예방 또는 치료용 약학적 조성물
KR20200035924A (ko) 2020-03-23 2020-04-06 주식회사 굳티셀 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
KR102317415B1 (ko) 2020-03-23 2021-10-28 주식회사 굳티셀 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
KR102429281B1 (ko) * 2020-05-25 2022-08-05 (주)노바셀테크놀로지 신규 안구건조증 치료용 약학적 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
AU2754600A (en) * 2000-02-04 2001-08-14 Us Health Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection

Also Published As

Publication number Publication date
WO2003064447A2 (en) 2003-08-07
CA2446872A1 (en) 2003-08-07
US20030224987A1 (en) 2003-12-04
EP1414849B1 (de) 2009-04-29
CN100569796C (zh) 2009-12-16
EP2108655A1 (de) 2009-10-14
KR100803092B1 (ko) 2008-02-18
KR100824685B1 (ko) 2008-04-24
EP1414849A2 (de) 2004-05-06
JP2010000077A (ja) 2010-01-07
KR20040012929A (ko) 2004-02-11
CA2446872C (en) 2012-03-20
KR100752756B1 (ko) 2007-08-29
KR20070108836A (ko) 2007-11-13
JP5232091B2 (ja) 2013-07-10
EP2108655B1 (de) 2013-11-20
CN101709078A (zh) 2010-05-19
JP4474163B2 (ja) 2010-06-02
CN1533399A (zh) 2004-09-29
KR20060114045A (ko) 2006-11-03
WO2003064447A3 (en) 2003-11-13
KR100839098B1 (ko) 2008-06-19
KR20060114046A (ko) 2006-11-03
CN101709078B (zh) 2013-04-17
JP2005521388A (ja) 2005-07-21
US7030090B2 (en) 2006-04-18

Similar Documents

Publication Publication Date Title
DE60327407D1 (de) Immunmodulierende peptide
DK1478328T3 (da) Bioaktive keratinpeptider
AU2003290563A8 (en) Leptin-related peptides
EP1578787A4 (de) Neue chi-conotoxinpeptide (-ii)
GB0324265D0 (en) Peptide
EP1558628A4 (de) Antigene peptide
PL375218A1 (en) Recombinant protein variants
NO20026285D0 (no) Nye peptider
ATE445634T1 (de) Antimikrobielle peptide
DE60334194D1 (de) Transmembranes nfat-hemmendes peptid
ATE419271T1 (de) Antimikrobielle peptide
NO20032963L (no) Peptidforbindelser
GB0218977D0 (en) Polypeptide
DK1625148T3 (da) Peptidkompleks
NO20050436D0 (no) Beta-lagnedbrytende peptider
GB0202275D0 (en) Peptide
NO20053512D0 (no) IL-8-liknende proteiner
DE602004022136D1 (de) Leukozyten stimulierende peptide
GB0217015D0 (en) Peptide 4
GB0205206D0 (en) Synthetic peptides
AU2003220217A8 (en) Identifying peptide modifications
GB0210746D0 (en) Peptide
NO20052608D0 (no) Midkinlignende protein
GB0219980D0 (en) Peptides
GB0208925D0 (en) Polypeptide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition